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Melatonin is a neuroendocrine hormone which regulates circadian rhythm and is also an
antioxidant. The role of melatonin in pregnancy is emerging. The enzymes needed for
endogenous synthesis of melatonin have been identified in the placenta, although the
contribution to circulating maternal melatonin in normal pregnancy is unclear. This work
aimed to determine serum levels of melatonin and its major metabolite 6-
hydroxymelatonin sulfate (6-OHMS) in normal pregnant women during each trimester of
pregnancy, and immediately after delivery. Blood samples were obtained from a cohort of
healthy pregnant women during each trimester of pregnancy (n = 26), from women
scheduled for elective Cesarean section (CS) before and after delivery (n = 15), along with
placental samples, and from healthy non-pregnant women as controls (n = 30). Melatonin
and its major metabolite, 6-OHMS, were measured using enzyme immunoassay. Levels of
serum melatonin were significantly higher during pregnancy than in non-pregnant women
(P = 0.025) and increased throughout pregnancy (P < 0.0001). In women undergoing CS,
serum melatonin decreased markedly 24 h after delivery (P = 0.0013). Similar results were
seen for serum levels of 6-OHMS, and placental tissue 6-OHMS levels correlated with
week of gestation at delivery (p = 0.018). In summary, maternal melatonin production is
higher in pregnant than in non-pregnant women, increases significantly during pregnancy
with highest levels in the third trimester, and decreases abruptly after delivery. These
results suggest that the placenta is a major source of melatonin and supports a
physiological role for melatonin in pregnancy.
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Oxidative stress is recognized as a potential pathophysiological
mechanism for placental disease such as pre-eclampsia (1).
Melatonin, as well as having a role in circadian rhythm
regulation, is also a powerful antioxidant with anti-inflammatory
actions (2, 3). Research has shown that melatonin has a role in
pregnancy, specifically in placental function and physiology (4, 5).
Earlier studies have reported higher melatonin levels in groups of
pregnant compared to non-pregnant women (6–8). In addition,
lower melatonin levels were seen in women with severe pre-
eclampsia, associated with the severity of pre-eclampsia as
shown in a meta-analysis (9).
Endogenous melatonin is synthesized from tryptophan via
serotonin under the control of N-acetylserotonin-O-methyl-
transferase, and aralkylamine-N-acetyl-transferase. Most
endogenous melatonin production takes place in the pineal
gland, regulated by light levels. However, ex vivo studies using
human placental and ovary tissue report melatonin synthesizing
enzymes capable of converting serotonin to melatonin (10–12).
Such non-pineal sources are not regulated by light and therefore
do not display circadian variation (13–15). However systematic
assessment of endogenous circulating melatonin metabolism as
pregnancy progresses, and identification of the placenta as the
source of melatonin in pregnancy has not been reported. The aim
of this study was to investigate circulating levels of melatonin and
its major bioactive metabolite, 6-hydroxymelatonin sulfate (6-
OHMS) during normal singleton pregnancy, compared to
healthy non-pregnant women of child bearing age, and the
contribution of the placenta.MATERIALS AND METHODS
Subjects and Study Design
The work presented here is from two linked prospective studies:
in MEL-P we recruited healthy pregnant women carrying a
single baby, plus healthy non-pregnant women of childbearing
age. We then went on to recruit a second cohort of healthy
pregnant women, also with singleton pregnancies, who were
scheduled for elective Cesarean section (CS). This study was
called MEL-P2. Both studies were prospectively registered at
ClinicalTrials.gov (NCT03014245 and NCT03609086
respectively) and were undertaken at Aberdeen Maternity
Hospital, NHS Grampian, Aberdeen, UK. The trials received
research ethics approval and written informed consent was
obtained from all participants.
Subjects
For both groups of pregnant women, women were excluded if
they were under 16 or over 45 years, were carrying more than
one baby or had a pre-pregnancy diabetes or hypertension,
chronic kidney disease, or any known autoimmune disorder.
For Study 1 (MEL-P) women with viable singleton pregnancies
were recruited after their first trimester antenatal ultrasoundFrontiers in Endocrinology | www.frontiersin.org 2scan at Aberdeen Maternity Hospital. Posters were placed in the
ultrasound department and following their scan, eligible women
were initially screened by antenatal clinical staff for eligibility and
then asked if they wished to speak to a researcher about the
study. Subjects who had abnormalities identified at the scan were
excluded. After written informed consent, morning venous blood
samples were obtained at 08:00–12:00 during each trimester (11–
12 weeks, 19–21 weeks, and 27–29 weeks gestation) and women
were followed up until delivery. To recruit healthy non-pregnant
women of childbearing age, emails were sent from a third party
to University and maternity staff email lists inviting non-
pregnant women up to the age of 45 years to respond if they
were interested in taking part. Anyone with any chronic
health condition and/or was taking medication was excluded.
After written informed consent, a single morning blood venous
blood sample was obtained at 08:00–12:00 from these
control subjects.
For study 2 (MEL-P2), pregnant women aged 16–45 years old
with singleton pregnancies who were scheduled for elective CS
were recruited. This study was designed to facilitate measurement
of melatonin shortly before and immediately after delivery and to
obtain placental tissue. After initial screening for eligibility by their
midwife or doctor, women attending routine CS pre-assessment
clinics were invited to speak with the researcher if they were
interested in participating. After written informed consent,
maternal morning blood samples were obtained at 08:00–12:00
between 3 and 6 days prior to elective CS and again 24 h after
delivery and placental tissue was obtained within 15 min
of delivery.
After delivery, gestational age at parturition, development of
preterm labor, gestational diabetes, pregnancy-induced hypertension
or pre-eclampsia were recorded for all pregnant participants.
Methods
Blood samples were collected into 5 ml clot activator-serum
separator vacutainers, allowed to clot and then centrifuged
within 2 h of collection, at 1,300 g for 10 min at room
temperature. Serum was stored at −80°C until assay. Placental
samples (1 cm3) were obtained from cotyledons that contained
the cytotrophoblast and syncytiotrophoblast, from two
diametrically opposed locations halfway between the center
and the placental border and through the entire depth of the
organ. Placental tissue samples were washed twice in Dulbecco’s
phosphate-buffered saline (PBS, Gibco, Paisley, UK) to remove
excess blood and snap frozen using a non-contact procedure
(FlashFREEZE, Milestone Srl, Italy) where cryovials containing
the samples were immersed in 1-methoxyheptafluoropropane
(Novec 7000 Engineered Fluid, 3M, St. Paul, MN, USA), to
achieve −80°C within 30 s. Frozen tissue was pulverized using a
mortar and pestle under liquid nitrogen and the resulting powder
(200 mg) was mixed with 2 ml PBS and pressed through a
100 mm strainer. Two cycles of freeze-thawing ensured rupture
of cell membranes and homogenates were then centrifuged at
5,000 g for 5 min at 4°C prior to analysis.
Commercially available competitive enzyme immunoassays
were used to measure melatonin (Wuhan Fine Biotech, Wuhan,February 2021 | Volume 11 | Article 623038
Ejaz et al. Melatonin in PregnancyChina) and 6-OHMS (Abbexa Ltd., Cambridge, UK) after
dilution, according to the manufacturer’s instructions. The
between-plate precision of these assays in our hands was 8.9%
for melatonin and 10.8% for 6-OHMS (coefficient of variation,
n = 6). The protein content of tissue homogenates was measured
using the Bradford technique with Coomassie Brilliant Blue dye
(16) using bovine serum albumin as calibration standard
(ThermoScientific, Rockford, IL, USA). All assays were
undertaken in duplicate.Statistical Analyses
Data were not normally distributed and are presented as median,
interquartile and full range. Statistical analysis was undertaken
using Analyse-It statistical add-in for Microsoft Excel using
Friedman test and Wilcoxon/Mann Whitney tests as
appropriate. Spearman’s correlation was used to assess the
relationship between gestational age and placental 6-OHMS content.
A p value less than 0.05 was accepted as statistically significant.Frontiers in Endocrinology | www.frontiersin.org 3RESULTS
Participant Characteristics
The CONSORT diagrams show recruitment for all participants
(Figures 1 and 2). Baseline characteristics of all participants are
shown in Table 1. All groups were similar in age. Pregnant
women had a slightly higher pre-pregnancy BMI than non-
pregnant controls. Figure 1 shows the CONSORT diagram for
MEL-P. Approximately 120 women presented for their first scan
and were screened for eligibility and willingness to talk to the
researcher about the study; two subsequently refused consent
and 30 were recruited. Two women withdrew consent before the
second trimester and a further two withdrew before the third
trimester, one due to identification of a fetal abnormality at
further scan at 20 weeks and another due to pregnancy loss at 26
weeks. Twenty-six women were followed to the third trimester.
Recruitment of the non-pregnant controls for MEL-P are
shown in Figure 1B. Of the 44 women who initially expressed an
interest, 35 were screened; 5 were ineligible due to chronic health
conditions and/or medication use other than oral contraceptives,
and 30 were recruited.
In MEL-P2, 35 women scheduled for CS were screened and
28 were eligible (Figure 2). Six were not eligible due to taking
medication for chronic health issues (n = 6), 7 were not recruited
due to incompatible CS dates, and one declined to take part. Six
women were lost to follow-up due to CS prior to the scheduled
date and 15 women were followed to delivery.
Clinical Outcomes
All pregnancies followed to delivery resulted in a term livebirth.
Nine of the women recruited in their first trimester (MEL-P) had
spontaneous vaginal deliveries, 12 were induced, and 5 had
elective CS, with no emergency CS or preterm deliveries. None
of the women had pre-eclampsia and only one developedA
B
FIGURE 1 | CONSORT diagrams for (A) MEL-P pregnant participants and
(B) MEL-P Non-pregnant healthy control subjects. FIGURE 2 | CONSORT diagram for MEL-P2 elective C-section participants.February 2021 | Volume 11 | Article 623038
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scheduled for elective CS (MEL-P2), two had gestational
diabetes (one taking metformin and other controlled by diet
only), two had asthma with no exacerbations, and one had a
congenital single kidney with no clinical symptoms of chronic
kidney disease or hypertension. The reasons for CS were:
previous CS (n = 6), breech presentation (n = 3), previous
third degree tear (n = 2), placenta previa (n = 2), genital
herpes (n = 1), and maternal request (n = 1).
Melatonin and 6-Hydroxymelatonin Sulfate
Serum concentrations of melatonin were variable between
individuals but were significantly higher in all trimesters in
pregnant women than the non-pregnant subjects (Figure 3,
P = 0.025, P = 0.04, and P = 0.0005 respectively). Levels of
melatonin increased significantly as pregnancy progressed, with
levels in the third trimester being around 3-fold higher than in
the first trimester (Figure 3, P < 0.0001). Serum levels of 6-
OHMS were also variable and were significantly higher in
pregnant women in all trimesters than in non-pregnant
controls (Figure 4, all P < 0.0001) although there was no
significant increase over pregnancy (Figure 4). We then went
on to recruit another cohort of women scheduled for CS toFrontiers in Endocrinology | www.frontiersin.org 4determine what happened to melatonin levels once the
pregnancy ended and to obtain placental tissue. Levels of
maternal serum melatonin and 6-OHMS at 3–6 days before CS
in the MEL-P2 cohort were similar to the levels seen in the third
trimester in the MEL-P patient cohort. Twenty-four hours after
CS, serum levels of both melatonin and 6-OHMS were markedly
decreased compared to before delivery (P = 0.0013 and P = 0.005
respectively, Figure 5). Both serum melatonin and 6-OHMS
levels 24 h after CS were slightly but significantly lower than in
the non-pregnant controls (P = 0.046 and P = 0.0025
respectively). The median (range) level of 6-OHMS in
placental tissue was 281.5 (217.1–346.8) pg/mg protein, which
correlated with gestational date in weeks (rs = 0.60, p = 0.018,
Figure 6). Data are summarized in Table 2.DISCUSSION
Our findings show that during normal pregnancy, circulating
maternal serum levels of melatonin and 6-OHMS, the major
metabolite of melatonin, increased markedly as pregnancy
progressed and were significantly higher than in a non-
pregnant cohort of similar age, even in the first trimester. In a
separate cohort of women undergoing elective CS, maternal
serum melatonin 3–6 days before delivery were also high and
decreased considerably immediately after delivery. High levels of
6-OHMS were also seen in placental tissue which correlated with
gestational age. These data show that melatonin production and/
or metabolism is markedly increased during normal pregnancy.
Furthermore, the levels of 6-OHMS found within placental tissue







Age (years) 28 [17–37] 26 [21–44] 31 [21–40]
BMI (Kg/M2) 24.1 [18.8–38.5] 22.0 [19.5–31.9] 33.7 [24.9 –43.1]Data shown as median [range]; BMI, body mass index.FIGURE 3 | Serum melatonin levels from MEL-P in non-pregnant healthy control subjects (n = 30) compared to pregnant subjects throughout pregnancy (n = 26),
*, significantly different from pregnant women in the first (P = 0.0025), second (P = 0.04), and third (P=0.0005) trimesters, Wilcoxon-Mann Whitney test. P value
shown is Friedman test over the trimesters showing increasing melatonin levels (P < 0.0001). Data are shown as median, interquartile, and full range with individual
raw data points overlaid.February 2021 | Volume 11 | Article 623038
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delivery suggests that the placenta is the source of the increased
maternal melatonin.
Both exogenously administered and endogenously produced
melatonin is rapidly metabolized, mainly in the liver, where it is
mostly hydroxylated by the cytochrome P450 enzymes CYP1A1
and CYP1A2 into 6-hydroxymelatonin, with a small proportion
de-methylated into N-acetylserotonin, along with limited
hydroxylation outside the liver by CYP1B1 (16). These
metabolites are either sulfated or glucoronidated, followed by
urinary excretion, with 6-OHMS accounting for about 80% of
the metabolic products (17, 18). Excretion levels of 6-OHMS in
urine are highly variable between individuals (19, 20) but levels
in serum are less so (20, 21). Levels of both melatonin and 6-
OHMS can be quantified by enzyme immunoassay; the assays
used here were highly specific, sensitive, and reproducible
competitive enzyme linked immunosorbent assays (ELISA).
We found here that melatonin and 6-OHM levels even in the
non-pregnant controls were higher than in previous reports. We
are unclear of the reason for this except that the method used
here was an immunoassay rather than a chemical assay such as
HPLC which is more generally used. Our results were consistent
according to our precision analysis and the manufacturers report
no cross reactivity between melatonin and similar compounds.
We have used the same methods for other samples, for example
after exogenous administration of melatonin to volunteers where
we found that levels were related to dose (20). This has no impact
on interpretation of our results. The high levels of melatonin and
6-OHMS in pregnant women could in theory represent either
increased melatonin production or increased metabolism;
increased production is more likely, since although metabolismFrontiers in Endocrinology | www.frontiersin.org 5of melatonin to 6-OHMS can be modulated by substances which
affect enzymes involved in either hydroxylation or sulfation,
these effects would decrease or delay metabolism; there are no
reports of increased melatonin metabolism.
Previous studies from several years ago have reported
melatonin levels during pregnancy in maternal, fetal and
umbilical cord blood, with some conflicting results (6–8).
Melatonin concentration in serum from different groups of
pregnant women and from the umbilical cord immediately
after birth was measured using radioimmunoassay in these
studies. No statistically significant differences in daytime
levels were seen but nighttime levels were significantly higher
than in non-pregnant women only after 24 weeks gestation (8).
Kivela (6) reported higher melatonin levels in late compared to
early pregnancy in different cohorts of women. Analyzing
samples from the same participants as pregnancy progresses is
important since there is such marked inter-individual variation
in metabolism due to the highly polymorphic nature of
cytochrome P450 enzymes (17, 20, 22). We found significantly
higher levels of melatonin and its major metabolite 6-OHMS
compared to non-pregnant controls, which increased as
pregnancy progressed and was coupled with marked decreases
after removal of the placenta. This suggests that melatonin
production in pregnancy is higher than non-pregnant women
and that the placenta appears to be the source of increased
circulating melatonin.
Our findings suggest that the placenta is the source of
increased circulating melatonin in pregnancy. However sources
from the mother and fetus as well as the placenta may also
contribute. Given the anti-inflammatory effects of melatonin it is
interesting to speculate that the high melatonin levels may beFIGURE 4 | Serum 6-hydroxymelatonin sulfate levels from MEL-P in non-pregnant healthy control subjects (n = 30) compared to pregnant subjects throughout
pregnancy (n = 26). **, significantly different from pregnant women in the first, second, and third trimesters (all P < 0.0001, Wilcoxon-Mann Whitney test). Data are
shown as median, interquartile, and full range. NS, non significant.February 2021 | Volume 11 | Article 623038
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Unlike in other studies (6, 8), the same patients were sampled
throughout pregnancy which both increased the power of the
study and minimized the contribution of inter-individual
variation. Our participants included only those with singleton
pregnancies; twin pregnancies are at higher risk of placental
dysfunction and specifically pre-eclampsia and melatonin may
be higher in twin pregnancies compared to singleton (8).
It was previously believed that endogenous melatonin from
the pineal gland was solely responsible for circulating melatonin
levels, but melatonin is present in most biological fluids and the
enzymes responsible for its synthesis have been identified in the
skin, immune cells, and the gastrointestinal tract (13, 14).
Relevant here are the ovary and placenta (10–12) which have
been reported to contain the enzymes needed for melatonin
synthesis. Melatonin synthesis by placental cells is assumed
although neither melatonin nor its metabolite levels have been
previously reported; our data uphold the suggestion that the
placenta is the source of high circulating maternal melatonin
levels. We can find no previous reports of measurement of
melatonin levels in human placenta apart from a study where
melatonin was detected in placentas that had been processed for
human consumption (24).
We found that maternal melatonin and 6-OHMS levels
decreased markedly after the pregnancy ended, 24 h after CS
(MEL-P2). A previous study some years ago also described lower
levels after delivery (7). It was previously reported that umbilical
cord blood melatonin concentrations differ in women giving
birth via spontaneous vaginal delivery compared to CS (22, 25).
It is not known what happens to melatonin levels during labor;
prolonged high levels may take longer to return to non-pregnant
levels than in women having CS. Melatonin has both antioxidant
and anti-inflammatory actions (2, 3). Cytokine responses in
women having CS are variable (22, 26) depending on
circumstances yet oxidative stress was lower and antioxidant
profile was augmented during CS delivery compared to
spontaneous vaginal delivery (27). In non-pregnant patients
undergoing major abdominal surgery, circulating melatonin
levels decrease but return to pre-operative values within 2 days
(28, 29), attributed to transient tumor necrosis factor a
-mediated suppression of gene expression of the melatonin
synthesizing enzymes. However, this is unlikely to explain the
marked fall in melatonin levels we found after delivery and a
more robust explanation is removal of the placenta. This area
requires further research.
The physiological function of the elevated placental
melatonin production remains unclear, but it could be
speculated that it may be related to preparation for parturition
and circadian regulation of melatonin receptor expression in
human myometrium has been reported (30). Human parturition
at term more commonly occurs late at night or early in the
morning whereas preterm labor shows no such diurnal variation
(29, 30). Our results coincide with the theory that melatonin may
be involved in instigation of labor with significantly higher levels
into the third trimester (15). This could have implications forFIGURE 6 | Relationship between placental 6-hydroxymelatonin sulfate levels
after elective C-section and gestational age in weeks (n = 15, P = 0.016,
Spearman’s test), from MEL-P2.A
B
FIGURE 5 | (A) Serum melatonin and (B) serum 6-hydroxymelatonin sulfate
levels in pregnant women (n = 15) 3–6 days before and 24 h after elective
C-section (MEL-P2). Levels were significantly after C-section (P = 0.0013 and
P = 0.005 respectively, Wilcoxon-Mann Whitney test). Data are shown as
median, interquartile, and full range.February 2021 | Volume 11 | Article 623038
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melatonin in labor require further investigation.
Given the increased levels of melatonin and 6-OHMS
compared with non-pregnant controls, even in the first
trimester, melatonin may have a role in maintaining normal
pregnancy. Of key clinical interest is whether low levels of melatonin
may have a role in diseases of pregnancy. Administration of
exogenous melatonin appears free of side effects in healthy
non-pregnant subjects (20, 31) and an open label phase I
single arm trial of exogenous melatonin in women with pre-
eclampsia reported that melatonin was safe for mothers and
fetuses (5). Exactly how melatonin may be involved in the
pathophysiology of pregnancy is vital to before moving on to
ascertain the potential for exogenous melatonin as a therapy to
prevent adverse obstetric outcomes.
In summary we report here marked increases in daytime levels
of melatonin and its major metabolite of melatonin in normal
pregnancy, which decreasedmarkedly after delivery, identifying the
placenta as the potential source of the high circulating maternal
melatonin levels. Increasing our understanding of the role of
melatonin in the physiology and pathophysiology of pregnancy is
vital, and confirmation of the role of the placenta in melatonin
production may lead to the use of melatonin as a preventative
treatment for obstetric conditions.
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